October 10, 2025
Shuttle to Enter $3.24 Billion AI Pharmaceutical Market
GAITHERSBURG, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a…
Pharmaceuticals, Biotechnology and Life Sciences
GAITHERSBURG, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a…
MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company…
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with…
REDWOOD CITY, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) — Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease…
Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical…
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory…
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY,…
Ohio-born cannabis brand brings personal story, community focus, and premium products to Silver Drive locationCOLUMBUS, Ohio, Oct. 09, 2025 (GLOBE…
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse modelsCAMBRIDGE, Mass., Oct. 09,…
Results from the study of oral gildeuretinol in moderate Stargardt disease to be presented as late-breaker during Retina Subspecialty DayCAMBRIDGE,…